MAIA MAIA Biotechnology, Inc. Insider Trading

MAIA CEO Vlad Vitoc bought 72,700 shares at $1.39 on 2026-06-01; prior 5 buys at MAIA all had positive 90d returns (+32.6% to +131.3%)

Vlad Vitoc, MAIA's Chief Executive Officer, purchased 72,700 shares at $1.39, increasing his holdings from 903.4K to 976.1K shares (+8.0%). This buy occurs against a backdrop of material stock decline: the current price of $1.30 represents a -59.2% drawdown from the 52-week high of $3.19, and the stock is down 13.9% over the past 90 days. The company remains unprofitable with net income of $-6.4M over its most recent fiscal year. However, Vitoc's timing pattern at MAIA is notable: all 5 of his prior trades at this ticker were well-timed at the 90-day mark, with prior 90-day returns ranging from +32.6% to +131.3%. His cross-ticker track record shows a 100.00% win rate across 5 buys with an average 90-day return of +116.6%. While the current price sits well below the transaction price and recent performance has been negative, the consistency of his prior well-timed accumulations at MAIA suggests pattern-based investor conviction at depressed valuations relative to recent highs.

Director Stan Smith purchased 75,000 MAIA shares at $1.34; adds to strong timing track record at this ticker while company unprofitable at $-6.4M net income.

Stan Smith, a director, acquired 75,000 shares of MAIA at $1.34 on 2026-06-01, increasing his holdings by 5.2% to 1,519,178 shares. His prior 5 trades at MAIA show a 5 of 5 pattern of well-timed purchases, with 90-day returns ranging from +19.3% to +133.0%, and his cross-ticker open-market history spans 16 buys with an 87.50% 90-day win rate and average 90d return of +47.3%. However, the current context is pressured: MAIA trades at $1.30 today, -59.2% from its 52-week high of $3.19 and down 13.9% over the past 90 days, while the company reported negative net income of $-6.4M in its most recent fiscal year. A cluster pattern is also present—2 other insiders bought within the past 14 days—suggesting coordinated accumulation at these depressed levels. The historical timing success does not guarantee future returns, especially in an unprofitable company with significant recent price deterioration.

Director Smith Stan bought 2,700 shares of MAIA at $3.69 on 2022-09-19; stock now $1.57 (-57.5% since trade).

Director Smith Stan purchased 2,700 shares at $3.69 on 2022-09-19, bringing his holdings to 1,444,178 shares. The company was unprofitable with net income of $-8,903,189.00 over its most recent full fiscal year. The current stock price of $1.57 represents a significant decline from the transaction price, and the current price remains -36.7% from the 52-week high of $2.48. His cross-ticker track record shows 18 prior buys with a 72.73% 90-day win rate and average 90d return of +23.6%, though at MAIA specifically, 0 of 0 prior buys were well-timed at the 90-day mark. The recent trading pattern at MAIA shows multiple buys in late 2025 with positive near-term returns, but the 2022-09-19 purchase has proven to be poorly timed in context of the stock's subsequent long-term decline.

Director Smith Stan purchases 57,189 shares of MAIA at $1.22; stock -45.2% from 52-week high; unprofitable company with cluster buying pattern

Smith Stan purchased 57,189 shares at $1.22 on 2025-12-22, bringing his total holdings to 1,421,478 shares. MAIA Biotechnology is currently trading at $1.36, which is -45.2% from its 52-week high of $2.48, though the stock has recovered +49.2% over the past 30 days. The company reported a net loss of $-8.9M over its most recent full fiscal year, operating as an unprofitable business. Notably, this purchase is part of a cluster pattern with 2 other insiders also buying within the past 14 days, and Smith Stan's prior MAIA purchases at this ticker all remain unmeasured (within their first 30 days), preventing assessment of execution quality at this specific ticker. His broader cross-ticker track record shows 17 prior open-market buys with a 70.00% 90-day win rate and +25.7% average 90-day return, but this historical performance across other securities does not directly predict success in an unprofitable biotech with recent steep losses.

MAIA Director CHAOUKI STEVEN M bought 40,849 shares at $1.22 (+36.8% holdings); unprofitable biotech with concurrent cluster buys.

Director Chaouki Steven M purchased 40,849 shares at $1.22, adding $50.0K and increasing his holdings by 36.8% to 151,873 shares. The timing context is mixed: his prior trade at MAIA on 2024-03-14 posted a +218.0% 90-day return (well-timed), but his most recent MAIA purchase on 2024-11-01 declined 25.9% over 90 days. His cross-ticker track record shows 50.0% win rate on prior buys with a 90-day average return of +96.0%, though sample size is small. This purchase occurs within a 14-day cluster of 2 other insider buys, which warrants attention. Against this stands the company's $-8.9M net loss over its last full fiscal year and current market cap of $50.4M, placing Maia in a biotech-stage profile where executive purchasing alone cannot substitute for fundamental progress.

Director Louie Ngar Yee bought 81,699 shares of MAIA at $1.22; insider's prior 3 MAIA buys all posted 90-day gains; company is unprofitable ($-8.9M net income); cluster buy pattern.

Louie Ngar Yee purchased 81,699 shares at $1.22 on 2025-12-22, increasing his holdings to 1.25M shares and joining 2 other insiders in buying MAIA within the past 14 days. His prior trade timing at MAIA is notably consistent: all 3 of his earlier purchases at this ticker (2024-04-25, 2024-03-14, 2023-04-27) delivered positive 90-day returns (+84.2%, +88.5%, and +2.2% respectively), indicating a pattern of well-timed entry points. The current environment presents a sharp contrast to his historical execution: MAIA trades 45.2% below its 52-week high and the company reported full-year net income of $-8.9M, highlighting fundamental weakness that stands apart from the price-action timing signal. The synchronized cluster buying by multiple insiders warrants monitoring alongside the insider's demonstrated historical pattern at this specific ticker, though the company's unprofitable status creates structural headwinds independent of insider positioning.

Director Smith Stan bought 13.7K shares at $1.20 blended average; MAIA unprofitable with -$8.9M net income; 2 other insiders also bought within 14 days.

On 2025-12-05, Director Stan Smith executed 3 separate purchases totaling 13,740 shares for $16,440.83 at a blended average price of $1.20. This accumulation occurs at a stock price 45.6% below the 52-week high and represents significant new conviction, occurring just days after his prior buys on 2025-11-26, 2025-11-25, and 2025-11-24. The cluster pattern—with 2 other insiders also buying within the past 14 days—suggests coordinated leadership conviction during a period of weakness. However, this conviction must be weighed against fundamentals: MAIA is deeply unprofitable, posting a net loss of $8,903,189.00 over its most recent full fiscal year and carries a modest $49,993,614.45 market cap, indicating investors are pricing in material distress or turnaround risk. Smith's cross-ticker buy history shows strong timing (70.00% 90-day win rate, average 90d return +25.7%), though at this ticker specifically, his limited measurable outcomes are mixed.

Director Stan Smith bought 15,000 shares of MAIA at $1.04; stock down -51.6% from 52-week high amid cluster buy pattern.

Director Stan Smith purchased 15,000 shares at $1.04 on 2025-11-26, raising his holdings to 1.36M shares, as MAIA trades at $1.20—down 51.6% from its 52-week high of $2.48 and off 20.0% over the past 90 days. This buy occurs within a cluster of 2 other insiders purchasing over the past 14 days, suggesting coordinated accumulation at depressed levels. Smith's cross-ticker track record shows strong timing discipline: 13 prior buys averaging +17.8% return in 30 days and +25.7% in 90 days, with a 70% win rate—though his 5 prior MAIA-specific trades are mixed, with 2 of 2 completed 90-day outcomes positive but the most recent three trades outcome-unmeasurable or still in loss territory (-4.6% at 30 days for the October purchase). The company remains unprofitable with net income of $-8.9M and a $44.4M market cap, adding material risk to the signal.

MAIA CEO Vitoc Vlad bought 72,000 shares at blended $1.11 average across 2 transactions; stock down 51.6% from 52-week high.

Vitoc Vlad, CEO of MAIA Biotechnology, purchased 72,000 shares in 2 transactions totaling $79,848.60, increasing his holdings by 9.2% to 853,421 shares. The purchases occurred at a blended average price of $1.11, while the stock currently trades at $1.20, down 51.6% from its 52-week high of $2.48 and down 20.0% over the past 90 days. His prior trades at MAIA show a timing pattern of 0 of 2 prior buys being well-timed at the 90-day mark, with historical 90-day returns of -8.0% and -22.5%. Additionally, the company is unprofitable, reporting net income of $-8,903,189.00 over its most recent full fiscal year. A cluster pattern is present, with 2 other insiders also buying within the past 14 days.

Director Luput Cristian buys 38,145 shares at avg $1.10; cluster pattern with 2 other insiders buying within 14 days

Luput Cristian (Director) executed two separate purchases totaling 38,145 shares for $41,845.86 at a blended average price of $1.10 on 2025-11-26 and 2025-11-28, increasing his holdings by 9.5% to 437,628 shares. A cluster pattern is present with 2 other insiders also buying within the past 14 days. However, his same-ticker history at MAIA shows mixed outcomes: of 5 prior trades, only 1 of 4 prior buys achieved positive 90-day returns (well-timed was the 2024-03-14 purchase at +218.0%), while three prior buys resulted in losses ranging from -12.0% to -40.6% at the 90-day mark. The company is unprofitable with net income of $-8,903,189.00 over its most recent full fiscal year, and the stock is -51.6% from its 52-week high, trading at $1.20 against a 52-week range of $0.87–$2.48. The concurrent buying by multiple insiders may indicate shared assessment of current valuation, but the director's own track record at this ticker shows a 25% success rate on prior buys.